Café

© 2026 Longbridge｜Terms of Service Privacy Policy

AN2 Therapeutics

ANTX

----

OverviewOverview NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

AN2 Therapeutics (ANTX)

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate in...

Open: --
High: --
Low: --
Prev. Close: --
Volume: --
Turnover: --
Avg Price: --
Bid/Ask Ratio: --
Amplitude: --
52wk High: --
Volume Ratio: --
Turnover Ratio: --

52wk Low: --
Float Mkt Cap: --
Market Cap: --
P/E^TTM: --
P/E^Dynamic: --
P/E^Static: --
EPS^TTM: --
EPS^Dynamic: --
EPS^Static: --
BVPS: --
P/B: --
Circulating Supply: --
Dividend Yield^TTM: --
Dividend^TTM: --
Shares: --
Min lot size: --
Currency: --

AN2 Therapeutics Analyst Rating

Forecast & Rating

Aug 14, 2026

Price forecast

$9.0083.67%

Forecast & RatingStrong buy

2analysts

Strong buy100.00%
Buy0.00%
Hold0.00%
Sell0.00%
Strong sell0.00%

Strong buy: 2
Buy: 0
Hold: 0
Sell: 0
Strong sell: 0

News

StockTitan · 1 day ago, 01:33 PM
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4) | ANTX Stock News
PUBT · Sep 11 at 11:46 PM
AN2 Therapeutics director Robin Shane Readnour disposes of 1,108 common shares worth $6,675
Global Report · Sep 9 at 10:12 AM
The Fringe Playbook: Finding Strategic Leverage in Niche Markets
Market Beat · Sep 9 at 01:08 AM
Anthem (NASDAQ:ANTX) Director Robin Shane Readnour Sells 6,100 Shares of Stock